Both rare and common variants in PCSK9 influence plasma low-density lipoprotein cholesterol level in American Indians.
Citation: Journal of Clinical Endocrinology & Metabolism. 100(2):E345-9, 2015 Feb.PMID: 25412415Institution: MedStar Health Research InstituteForm of publication: Journal ArticleMedline article type(s): Journal Article | Research Support, N.I.H., ExtramuralSubject headings: *Cholesterol, LDL/bl [Blood] | *Genetic Variation | *Indians, North American/ge [Genetics] | *Proprotein Convertases/ge [Genetics] | *Serine Endopeptidases/ge [Genetics] | Adult | Female | Genotype | Humans | Male | Middle Aged | Mutation | Polymorphism, Single Nucleotide | Young AdultLocal holdings: Available online through MWHC library: 1999- June 2013, Available in print through MWHC library: 1999 - 2006ISSN:- 0021-972X
Item type | Current library | Collection | Call number | Status | Date due | Barcode |
---|---|---|---|---|---|---|
Journal Article | MedStar Authors Catalog | Article | Available | 25412415 |
Available online through MWHC library: 1999- June 2013, Available in print through MWHC library: 1999 - 2006
CONCLUSIONS: Both rare and common variants in PCSK9 influence plasma LDL-C levels in American Indians. Follow-up studies may disclose the influence of these mutations on the risk of CVD and responses to cholesterol-lowering medications.
CONTEXT: Elevated LDL cholesterol (LDL-C) is an important risk factor for atherosclerosis and cardiovascular disease. Variants in the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene have been associated not only with plasma LDL-C concentration, but also with ischemic heart disease. Little is known about the genetic architecture of PCSK9 and its influence on LDL-C in American Indians.
DESIGN: The Strong Heart Family Study (SHFS) is a family-based genetic study.
OBJECTIVE: We aimed to investigate the genetic architecture in the 1p32 region encompassing PCSK9 and its influence on LDL-C in American Indians.
PARTICIPANTS: Two thousand four hundred fifty eight American Indians from Arizona, Oklahoma, North Dakota, and South Dakota, who were genotyped by Illumina MetaboChip.
RESULTS: We genotyped 486 SNPs in a 3.9 Mb region at chromosome 1p32 encompassing PCSK9 in 2458 American Indians. We examined the association between these SNPs and LDL-C. For common variants (MAF > 1%), meta-analysis across the three geographic regions showed common variants in PCSK9 were significantly associated with higher LDL-C. The most significant SNP rs12067569 (MAF = 1.7 %, beta = 16.9 +/- 3.7, P = 5.9 x 10(-6)) was in complete LD (r(2) = 1) with a nearby missense SNP, rs505151 (E670G) (beta = 15.0 +/- 3.6, P = 3.6 x 10(-5)). For rare variants (MAF < 1%), rs11591147 (R46L, MAF = 0.9%) was associated with lower LDL-C (beta = - 31.1 +/- 7.1, P = 1.4 x 10(-5)). The mean (SD) of LDL-C was 76.9 (7.8) and 107.4 (1.0) mg/dL for those with and without the R46L mutation, respectively. One person who was homozygous for R46L had LDL-C levels of 11 mg/dL. In one family, 6 out of 8 members carrying the R46L mutation had LDL-C levels below the lower 10% percentile of LDL-C among all study participants.
English